Elexacaftor clinical trials
Counted the way a researcher would: Elexacaftor with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.
This browser remembers your choice.
How each study uses elexacaftor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the elexacaftor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 21 Oct 2019 · TRIKAFTA (COPACKAGED) · NDA 212273 (FDA, Drugs@FDA; in a combination)
- European Union
- 21 Aug 2020 · Kaftrio · EMEA/H/C/005269 (EMA; in a combination)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
23 studies that test it; most in 2020 (5)
| Year | Studies |
|---|---|
| 2017 | 1 |
| 2018 | 2 |
| 2019 | 4 |
| 2020 | 5 |
| 2021 | 3 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 20 · Other 3
Vertex Pharmaceuticals Incorporated (20) · Royal College of Surgeons, Ireland (1) · Istituto Giannina Gaslini (1) · Arkansas Children's Hospital Research Institute (1)
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 2, 2 in phase 3
Studies that test elexacaftor, phase 3 first.
- Apr 2027Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delPhase 3 · Vertex Pharmaceuticals Incorporated
- Sep 2027Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderPhase 3 · Vertex Pharmaceuticals Incorporated
Studies
Open first, then newest update. How each study uses elexacaftor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 23
- Pharmacokinetics of Elexacaftor/Tezacaftor/Ivacaftor in Cystic FibrosisRecruitingPhase 4Istituto Giannina GasliniNCT07809867Written as Elexacaftor, Tezacaftor, IvacaftorHow we know
- Ensuring Access to Optimal Therapy in CF: The ENACT StudyRecruitingPhase 4Arkansas Children's Hospital Research InstituteNCT07148739Written as Elexacaftor / Ivacaftor / TezacaftorHow we know
- Study to Evaluate Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) Long-term Safety and Efficacy in Subjects Without F508delActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT05331183Written as ELX/TEZ/IVAHow we know
- Evaluation of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis (CF) Participants 12 to Less Than 24 Months of AgeCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05882357Written as ELX/TEZ/IVAHow we know
- Real World Clinical Outcomes With Novel Modulator Therapy Combinations in People With CF (RECOVER)Active, not recruitingPhase 4Royal College of Surgeons, IrelandNCT04602468Written as Elexacaftor/Tezacaftor/IvacaftorHow we know
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis Participants 12 Months of Age and OlderActive, not recruitingPhase 3Vertex Pharmaceuticals IncorporatedNCT06460506Written as ELX/TEZ/IVAHow we know
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05153317Written as ELX/TEZ/IVAHow we know
- A Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT03525574Written as ELX/TEZ/IVAHow we know
- A Study to Evaluate ELX/TEZ/IVA on Cough and Physical Activity in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04969224Written as ELX/TEZ/IVAHow we know
- Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA TC Combination Therapy in Participants With Cystic Fibrosis Who Are 6 Years of Age and OlderCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04183790Written as ELX/TEZ/IVAHow we know
- Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05274269Written as ELX/TEZ/IVAHow we know
- A Study Evaluating the Long-term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis (CF) Particpants 6 Years and Older and F/MF GenotypesCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04545515Written as ELX/TEZ/IVAHow we know
- Study Evaluating the Long-term Safety and Efficacy of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04058366Written as ELX/TEZ/IVAHow we know
- A Study to Assess the Effect of ELX/TEZ/IVA on Glucose Tolerance in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04599465Written as ELX/TEZ/IVAHow we know
- A Study Evaluating the Long-Term Safety of Elexacaftor Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04362761Written as ELX/TEZ/IVAHow we know
- A Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor in Participants With Cystic Fibrosis (CF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05111145Written as ELX/TEZ/IVAHow we know
- A Study Evaluating the Long-term Safety of VX-445 Combination TherapyCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04043806Written as ELX/TEZ/IVAHow we know
- Evaluation of ELX/TEZ/IVA in Cystic Fibrosis (CF) Subjects 2 Through 5 YearsCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04537793Written as ELX/TEZ/IVAHow we know
- A Study Evaluating Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Subjects 6 Through 11 Years of Age With Cystic Fibrosis and F/MF GenotypesCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT04353817Written as ELX/TEZ/IVAHow we know
- A Study of VX-445 in Healthy Subjects and Subjects With Cystic FibrosisCompletedPhase 1/2Vertex Pharmaceuticals IncorporatedNCT03227471Written as VX-445How we know
See all 23 studies that test elexacaftor →
Given beside what is tested · 1 — elexacaftor is usual care or a partner of the new treatment
As the comparator · 2 — what is tested is compared with elexacaftor
- A Phase 3 Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Heterozygous for F508del and a Minimal Function Mutation (F/MF)CompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05033080Written as ELX/TEZ/IVAHow we know
- A Study of VX-121 Combination Therapy in Participants With Cystic Fibrosis (CF) Who Are Homozygous for F508del, Heterozygous for F508del and a Gating (F/G) or Residual Function (F/RF) Mutation, or Have At Least 1 Other Triple Combination Responsive (TCR) CFTR Mutation and No F508del MutationCompletedPhase 3Vertex Pharmaceuticals IncorporatedNCT05076149Written as ELX/TEZ/IVAHow we know
Codes
What other systems call elexacaftor · ClinicalTrials.gg INT001009
- MeSH (NLM) C000629074elexacaftorConfirmed ClinicalTrials.gov, NLM
- UNII (FDA) RRN67GMB0VELEXACAFTORConfirmed FDA, NLM, Wikidata
- RxNorm 2256951Confirmed FDA, Wikidata
- Wikidata Q72184089elexacaftorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C169935ElexacaftorOne source FDA
- DrugBank DB15444One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000629074 | elexacaftor | Confirmed ClinicalTrials.gov, NLM |
| UNII (FDA) | RRN67GMB0V | ELEXACAFTOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2256951 | — | Confirmed FDA, Wikidata |
| Wikidata | Q72184089 | elexacaftor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C169935 | Elexacaftor | One source FDA |
| DrugBank | DB15444 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.